SA
CRSP icon

Strategic Advocates’s CRISPR Therapeutics CRSP Stock Holding History

Strategic Advocates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.6K Sell
1,147
-182
-14% -$9.59K 0.24% 76
2026
Q1 		$63.2K Buy
1,329
+134
+11% +$7.07K 0.28% 65
2025
Q4 		$63.6K Buy
1,195
+670
+128% +$40.1K 0.02% 180
2025
Q3 		$34K Buy
+525
New +$30.1K 0.01% 227

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Strategic Advocates's CRSP Position: Q2 2026 in Review

Strategic Advocates reduced its CRISPR Therapeutics (CRSP) stake by 14% in Q2 2026, selling an estimated $9.59K and leaving 1,147 shares worth $62.6K. The position accounts for 0.24% of the portfolio, ranked #76.

Strategic Advocates first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $63.6K in Q4 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Strategic Advocates held 1,147 shares of CRISPR Therapeutics worth $62.6K as of Q2 2026.
  • Strategic Advocates sold 182 CRISPR Therapeutics shares in Q2 2026, an estimated $9.59K.
  • CRISPR Therapeutics made up 0.24% of Strategic Advocates's portfolio in Q2 2026, its #76 holding.
  • Strategic Advocates first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Strategic Advocates's CRISPR Therapeutics position peaked at $63.6K in Q4 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.